<DOC>
	<DOCNO>NCT02956551</DOCNO>
	<brief_summary>The study aim test efficacy safety neoantigen-primed T cell therapy refractory non-small cell lung cancer .</brief_summary>
	<brief_title>Neoantigen-primed Dendritic Cells ( DC ) - Pre-activated T ( PreT ) Cell Therapy Refractory Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Patients pathological confirm non-small cell lung cancer standard treatment enrol . The patient fail previous least 2 line chemotherapy 1 line target therapy applicable . This prospective exploratory trial . Patients ' rebiopsy tumor tissue subsequent whole exosome sequence possible neoantigens identify . DC vitro prim synthesized peptide . Patients treat DC-primed T cell . Both adverse event response record .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>pathologically confirm nonsmall cell lung cancer fail previous standard chemotherapy target therapy anticipated life time &gt; 3month Karnofsky performance status 01 rehabilitate previous therapy adequate organ function mixed histological type tumor emergency abnormal coagulation condition contagious disease , HBV , HCV , HIV , TB infection concomitant tumor immunological comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>advanced non-small cell lung cancer</keyword>
	<keyword>cell base therapy</keyword>
	<keyword>safety</keyword>
	<keyword>clinical efficacy</keyword>
</DOC>